These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 34788985)
1. Mutational landscape of high-grade B-cell lymphoma with Künstner A; Witte HM; Riedl J; Bernard V; Stölting S; Merz H; Olschewski V; Peter W; Ketzer J; Busch Y; Trojok P; Bubnoff NV; Busch H; Feller AC; Gebauer N Haematologica; 2022 Aug; 107(8):1850-1863. PubMed ID: 34788985 [TBL] [Abstract][Full Text] [Related]
2. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716 [TBL] [Abstract][Full Text] [Related]
3. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry. Lešková K; Szépe P; Balhárek T; Barthová M; Janáková Ľ; Farkašová A; Plank L Neoplasma; 2022 Jul; 69(4):957-964. PubMed ID: 35652622 [TBL] [Abstract][Full Text] [Related]
4. [The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data]. Misyurina AE; Kravchenko SK; Kovrigina AM; Magomedova AU; Plastinina LV; Obukhova TN; Misyurin AV; Misyurin VA; Grebenuk LA; Babaeva FE; Baryakh EA; Vorobiev AI Ter Arkh; 2019 Jul; 91(7):52-62. PubMed ID: 32598736 [TBL] [Abstract][Full Text] [Related]
5. Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups? Blomme S; De Paepe P; Devos H; Emmerechts J; Snauwaert S; Cauwelier B Genes Chromosomes Cancer; 2024 Jan; 63(1):e23211. PubMed ID: 37897298 [TBL] [Abstract][Full Text] [Related]
6. High-grade B-cell lymphoma with Scott DW; King RL; Staiger AM; Ben-Neriah S; Jiang A; Horn H; Mottok A; Farinha P; Slack GW; Ennishi D; Schmitz N; Pfreundschuh M; Nowakowski GS; Kahl BS; Connors JM; Gascoyne RD; Ott G; Macon WR; Rosenwald A Blood; 2018 May; 131(18):2060-2064. PubMed ID: 29475959 [TBL] [Abstract][Full Text] [Related]
7. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. Baptista MJ; Tapia G; Muñoz-Marmol AM; Muncunill J; Garcia O; Montoto S; Gribben JG; Calaminici M; Martinez A; Veloza L; Martínez-Trillos A; Aldamiz T; Menarguez J; Terol MJ; Ferrandez A; Alcoceba M; Briones J; González-Barca E; Climent F; Muntañola A; Moraleda JM; Provencio M; Abrisqueta P; Abella E; Colomo L; García-Ballesteros C; Garcia-Caro M; Sancho JM; Ribera JM; Mate JL; Navarro JT Histopathology; 2022 Dec; 81(6):826-840. PubMed ID: 36109172 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Miyaoka M; Kikuti YY; Carreras J; Ikoma H; Hiraiwa S; Ichiki A; Kojima M; Ando K; Yokose T; Sakai R; Hoshikawa M; Tomita N; Miura I; Takata K; Yoshino T; Takizawa J; Bea S; Campo E; Nakamura N Mod Pathol; 2018 Feb; 31(2):313-326. PubMed ID: 28984304 [TBL] [Abstract][Full Text] [Related]
9. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma. Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538 [TBL] [Abstract][Full Text] [Related]
10. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas. Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279 [TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907 [No Abstract] [Full Text] [Related]
12. Clinical significance of 'double-hit' and 'double-expression' lymphomas. Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842 [TBL] [Abstract][Full Text] [Related]
13. Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6). Witte HM; Riedl J; Künstner A; Fähnrich A; Ketzer J; Fliedner SMJ; Reimer N; Bernard V; von Bubnoff N; Merz H; Busch H; Feller A; Gebauer N Target Oncol; 2023 Sep; 18(5):749-765. PubMed ID: 37488307 [TBL] [Abstract][Full Text] [Related]
14. High-Grade B-Cell Lymphoma (HGBL) with Tsai CC; Su YC; Bamodu OA; Chen BJ; Tsai WC; Cheng WH; Lee CH; Hsieh SM; Liu ML; Fang CL; Lin HT; Chen CL; Yeh CT; Lee WH; Ho CL; Lai SW; Tzeng HE; Hsieh YY; Chang CL; Zheng YM; Liu HW; Yen Y; Whang-Peng J; Chao TY Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807449 [TBL] [Abstract][Full Text] [Related]
15. High grade B-cell lymphoma with Ferrari A; Arniani S; Crescenzi B; Ascani S; Flenghi L; Pierini V; Moretti M; Beacci D; Romoli S; Bardelli V; Calistri D; Martinelli G; Mecucci C; La Starza R Leuk Lymphoma; 2022 Jun; 63(6):1356-1362. PubMed ID: 35045798 [TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma. Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646 [TBL] [Abstract][Full Text] [Related]
17. Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement. Carreras J; Ikoma H; Kikuti YY; Miyaoka M; Hiraiwa S; Tomita S; Kondo Y; Ito A; Nagase S; Miura H; Kawada H; Roncador G; Campo E; Hamoudi R; Nakamura N Virchows Arch; 2024 Apr; 484(4):657-676. PubMed ID: 38462571 [TBL] [Abstract][Full Text] [Related]
18. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. Krull JE; Wenzl K; Hartert KT; Manske MK; Sarangi V; Maurer MJ; Larson MC; Nowakowski GS; Ansell SM; McPhail E; Habermann TM; Link BK; King RL; Cerhan JR; Novak AJ Blood Cancer J; 2020 Nov; 10(11):117. PubMed ID: 33168821 [TBL] [Abstract][Full Text] [Related]
19. The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS. Hüttl KS; Staiger AM; Richter J; Ott MM; Kalmbach S; Klapper W; Biesdorf AS; Trümper L; Rosenwald A; Ziepert M; Horn H; Ott G Virchows Arch; 2021 Sep; 479(3):575-583. PubMed ID: 33655392 [TBL] [Abstract][Full Text] [Related]
20. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Huang W; Medeiros LJ; Lin P; Wang W; Tang G; Khoury J; Konoplev S; Yin CC; Xu J; Oki Y; Li S Mod Pathol; 2018 Sep; 31(9):1470-1478. PubMed ID: 29785017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]